Evaluation of concomitant treatment for Chronic Pelvic Pain Syndrome

Chronic prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) is a common and challenging condition with no consensus on the best treatment. Also, based on a search in reputable scientific databases, it was found that so far, no study has been conducted to evaluate the response to treatment with concomitant use of tamsulosin, levofloxacin, and celecoxib in chronic pelvic pain syndrome in men.

Ninety six male patients under 40 years of age with chronic pelvic pain syndrome who met the inclusion criteria and exclusion criteria were included in the study. Patients (there was only one group of patients in this study) were treated simultaneously with 3 drugs tamsulosin (0.4 mg), levofloxacin (500 mg), and celecoxib (200 mg) for 1 month and after 1 month of treatment response to treatment (pain relief) according to age factors. Weight, underlying disease, smoking, BMI, prostatitis family history, and education were recorded by the researcher in preprepared data collection forms. The results and information obtained were entered into statistical software and analyzed.

About 42.7% of patients experienced pain relief after treatment. Age, smoking, and family history of prostatitis showed significant relationships with pain reduction. Weight gain decreased the chances of pain reduction (OR = 0.303), while increased BMI (OR = 0.476) and smoking (OR = 0.801) also negatively influenced pain relief.

The results of this study showed that the concomitant use of tamsulosin, levofloxacin and celecoxib in patients with chronic pelvic pain syndrome had acceptable results in reducing the symptoms of patients.